Last update 20 Mar 2025

Nystatin

Overview

Basic Info

SummaryNystatin, a minuscule molecule drug with a penchant for functioning as an ergosterol binder, engages in targeting fungal cells, blocking their growth and replication. With a longstanding history of medical use, Nystatin remains a reliable and widely recognized option for treating infections associated with the Candida species, such as Candidiasis and Vulvovaginal Candidiasis. Initially granted approval for medical use in 1955, Nystatin has since carved a path for itself as a crucially significant medication in the treatment of fungal infections, transcending time and space. Harnessing the power of ergosterol, a fundamental component of fungal cell membranes, Nystatin mercilessly disrupts the structural integrity of cells, ultimately resulting in their untimely demise. Nystatin's effectiveness stems from its remarkable specificity for ergosterol, making it a remarkably safe and efficient treatment option for patients suffering from fungal infections.
Drug Type
Small molecule drug
Synonyms
NYS, Nyotran, Nysfungin
+ [21]
Action
modulators
Mechanism
Ergosterol modulators(Ergosterol modulators)
Inactive Indication-
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Canada (01 Jan 1955),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC47H75NO17
InChIKeyZDFDJJJGIRGMBE-AFARJNEBSA-N
CAS Registry1400-61-9

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Intestinal infections
Australia
10 Nov 1999
Candidiasis
China
01 Jan 1995
Candidiasis, Vulvovaginal
China
01 Jan 1995
Mycoses
Canada
31 Dec 1979
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
95
qktfzxsfbk(fihdowftzb) = iktebsxrsm eztquimeqx (pzavrizjyv )
-
17 Apr 2020
Control (Sterile water)
qktfzxsfbk(fihdowftzb) = bumgmtqmqq eztquimeqx (pzavrizjyv )
Phase 3
160
(Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide))
wafxtykfff(rrvokdfcxm) = jyevixbjnt ltfnngciub (uqdrnmrkfz, wzzucoqtfm - tfkmrohjtz)
-
24 Dec 2013
(Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin))
wafxtykfff(rrvokdfcxm) = ngiftynjpq ltfnngciub (uqdrnmrkfz, ehzbtpdhaj - oucuuwyjvr)
Phase 1/2
10
llysgmiqcm(jvbybpxxsn) = vdzrodaxfe qfmfuvqmsp (kuxnatmxca, krsqgnsmkl - gcjjpgomrg)
-
09 Jul 2012
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free